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Abstract. Human chromosome 11p11.2 contains a putative
liver tumor suppressor locus that was identified using a
microcell hybrid cell line-based model of tumor suppression.
Transcription mapping of suppressed microcell hybrid cell
lines suggests that human SYT13 represents a strong
candidate for the 11p11.2 tumor suppressor gene. Other
evidence suggests that the putative 11p11.2 tumor suppressor
gene (SYT13 or some other) may modulate the tumori-
genic potential of neoplastic liver cell lines through direct
or indirect regulation of the rat Wt1 tumor suppressor
gene. To characterize a functional role for SYT13 in liver
tumor suppression, we employed RNAi to attenuate SYT13
expression in a suppressed microcell hybrid cell line
(GN6TF-11neoCX4). SYT13-attenuated cells display
aggressive phenotypic properties that are similar to or
indistinguishable from the parental tumor cells (GN6TF),
including altered cellular morphologies, disrupted contact
inhibition, elevated saturation densities, restoration of
anchorage-independent growth and increased tumorigenicity
in vivo. Moreover, SYT13 attenuation and re-expression of
tumorigenicity in GN6TF-11neoCX4-derived cell lines was
accompanied by a significant decrease of Wt1 expression. In
contrast, the phenotypic properties of scrambled-control cells
were similar to the suppressed microcell hybrid cells and
Wt1 expression was unaffected. These observations combine
to establish that: i) human SYT13 functions as a liver tumor
suppressor gene that complements a molecular defect in
GN6TF rat liver tumor cells resulting in a normalized cellular
phenotype in vitro and suppression of tumorigenicity in vivo;
ii) RNAi-mediated attenuation of SYT13 expression restores
the neoplastic phenotype of GN6TF-11neoCX4 microcell
hybrid cells, consistent with the function of a liver tumor
suppressor gene; and iii) loss of Wt1 expression is important
for the re-establishment of tumorigenic potential by GN6TF-
11neoCX4 microcell hybrid cells after attenuation of SYT13.
Introduction
Hepatocellular carcinogenesis is a multi-step process that
results from altered expression of multiple genes as a
consequence of genetic mutations, epigenetic mechanisms,
and/or chromosomal aberrations affecting a number of
chromosome arms (1,2), including chromosome 11p (3-6).
Comparative mapping studies suggest strongly that hepato-
carcinogenesis in humans and rodents may be governed
by orthologous tumor suppressor genes (7). We exploited
this supposition to identify human liver tumor suppressor
genes using a functional model for tumor suppression based
on microcell-mediated transfer of human chromosome 11
into the aggressive rat liver tumor cell line GN6TF (8). The
resulting microcell hybrid cell lines exhibit normalized
cellular morphology, re-expression of contact inhibition,
complete loss of anchorage-independent growth potential,
and decreased tumorigenicity in vivo, suggesting that
human chromosome 11 contains one or more liver tumor
suppressor genes (8). Genomic mapping localized the liver
tumor suppressor locus to a small (<1 Mbp) region of human
chromosome 11p11.2 containing a number of candidate
genes (9,10). Subsequently, transcription mapping identified
several candidate 11p11.2 tumor suppressor genes (including
TP53I11, PRDM11, LOC219638 and SYT13) that were
expressed in a panel of suppressed microcell hybrid cell
lines (11,12). SYT13 mRNA was detected in 100% of
suppressed microcell hybrid cell lines and was absent in all
non-suppressed clones, including a non-suppressed microcell
hybrid cell line that contains chromosome 11 with an
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interstitial deletion at the suppressive 11p11.2 locus
(11,13). Finally, SYT13 expression was lost in all microcell
hybrid-derived tumor cell lines examined, coordinate with re-
expression of the tumorigenic phenotype (11). Based on its
differential expression among microcell hybrid cell lines,
SYT13 emerged as an excellent candidate for the human
11p11.2 liver tumor suppressor gene. The mechanism of
SYT13-mediated tumor suppression in this model system
is not yet known. However, induction of rat Wt1 gene
expression accompanies suppression of tumorigenicity by
human 11p11.2 (14), suggesting that the 11p11.2 liver tumor
suppressor gene (SYT13 or some other gene) may directly or
indirectly regulate Wt1 gene expression. Based upon the
results of these studies, we propose that: i) SYT13 represents
an excellent candidate for the human 11p11.2 liver tumor
suppressor gene; and ii) the tumor suppressor function of
SYT13 may be mediated through (or require) expression of
the rat Wt1 gene.
To characterize the mechanistic role of SYT13 in this
model of liver tumor suppression, we analyzed phenotypic
alterations in the suppressed microcell hybrid cell line
GN6TF-11neoCX4 after stable silencing of human SYT13
utilizing RNA interference (RNAi). Cells were transfected
with an expression vector encoding a SYT13-specific short
hairpin dsRNA (shRNA), resulting in a severe attenuation of
SYT13 protein expression. SYT13-targeted cell lines display
aggressive phenotypic properties similar to the parental
GN6TF tumor cells, consistent with the suggestion that
SYT13 functions as a tumor suppressor in this model system.
Cell morphologies were altered, saturation densities were
elevated, anchorage-independent growth was restored, and
tumorigenicity in vivo was significantly increased. In
addition, rat Wt1 gene expression levels were depressed in
SYT13-attenuated cell lines, suggesting that loss of Wt1 may
contribute to the expression of the aggressive phenotypic
characteristics. In contrast, cell lines expressing a scrambled
control SYT13 shRNA retain a robust level of Wt1 expression
and display a phenotype both in vitro and in vivo similar
to that of the suppressed GN6TF-11neoCX4 cells. These
observations combine to establish that: i) human SYT13
functions as a liver tumor suppressor gene that complements
a molecular defect in GN6TF rat liver tumor cells resulting
in a normalized cellular phenotype in vitro and suppression
of tumorigenicity in vivo; ii) RNAi-mediated attenuation
of SYT13 expression restores the neoplastic phenotype of
GN6TF-11neoCX4 microcell hybrid cells, consistent with the
function of a liver tumor suppressor gene; and iii) loss of
Wt1 expression is important for the re-establishment of
tumorigenic potential by GN6TF-11neoCX4 microcell hybrid
cells after attenuation of SYT13, consistent with the possibility
that Wt1 is the ultimate tumor suppressor gene in this model
system.
Materials and methods
Cell lines and culture. The rat liver epithelial tumor cell
line GN6TF (15) was derived from a normal rat liver
epithelial cell line (termed WB-F344) that has been described
previously (16). Microcell hybrid cell lines were established
from GN6TF rat liver tumor cells (8,13) by microcell-
mediated chromosome transfer of human chromosome 11,
using established methods (17,18). Clonal GN6TF-11neo
microcell hybrid cell lines used for chromosome deletion
and transcription mapping have been described (11). In the
current study, GN6TF-11neoCX4 cells were transfected with
shRNA expression constructs (as described below). All
phenotypic and gene expression-related comparisons were
made relative to GN6TF tumor cells and GN6TF-11neoCX4
microcell hybrid cells. All cell lines were cultured in
Richter's minimal essential medium supplemented as
described (19). GN6TF-11neoCX4 cells (and derived cell
lines) were maintained in medium containing 800 μg/ml
G418 (8). After transfection with shRNA vectors, cell lines
derived from GN6TF-11neoCX4 cells were maintained in
medium containing 180 μg/ml Zeocin (InvivoGen, San
Diego, CA).
Short hairpin-RNA expression vectors. Expression vectors
for SYT13 shRNA (and scrambled control shRNAs) were
constructed using psiRNA-hH1zeo (InvivoGen). This plasmid
contains a BbsI cloning site downstream of the H1 promoter
which drives the expression of a short dsRNA hairpin
structure, as well as an Sh Ble expression cassette (under
the control of the EM7 promoter) which confers resistance
to Zeocin. Targeting oligodeoxynucleotides (designated
SYT13-i), designed according to guidelines provided by
InvivoGen, were directed against a 21 base pair target in
exon 2 of hSYT13 (Fig. 1) which has 71% (15/21) sequence
identity to the rat Syt13 gene. Control oligodeoxynucleotides
(designated SYT13-s) were generated by scrambling
nucleotides of the SYT13-i targeting sequence (SYT13-i,
5'-AGA CTA TTC ACT GAG GTC TAC-3'; SYT13-s, 5'-A
GC ATA TTC CAT GAG GTC TAC-3') (Fig. 1). Oligo-
deoxynucleotides corresponding to sense and anti-sense
strands for both the SYT13-i and SYT13-s sequences were
synthesized by the UNC Oligodeoxynucleotide Core Facility
(Chapel Hill, NC). These oligodeoxynucleotides were
denatured, annealed, cloned into the psiRNA-hH1zeo
plasmid and propagated in E. coli GT116 (InvivoGen).
Plasmids were purified using the Wizard Midiprep kit
from Qiagen (Madison, WI) and sequenced by the UNC
DNA Core Sequencing Facility to verify the construction
of the shRNA expression cassettes.
Production of stably transfected SYT13-targeted and control
cell clones. Transfection and stable integration of DNA
vectors into the GN6TF-11neoCX4 cell line was achieved using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to
the protocol provided by the manufacturer. Purified plasmid
DNA (5 μg) was linearized by SwaI digestion and then trans-
fected into 8.6x105 cells. Successfully transfected cells were
selected in 180 μg/ml Zeocin (InvivoGen), and individual
cell lines (designated with the prefix SYT13-i and SYT13-s,
respectively) were clonally isolated and maintained in culture
as previously described (11).
Gene expression analysis. Transcriptional analyses of
SYT13-i and SYT13-s cell lines included semi-quantitative
RT-PCR and/or quantitative real-time RT-PCR for various
gene targets. Total cellular RNA was isolated from cultured
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cells using RNeasy (Qiagen, Valencia, CA) according to
the manufacturer's guidelines. For quantitative reverse
transcription-PCR, oligodeoxynucleotides to rat Wt1 were
designed around intron-exon boundaries using Primer
Express software (Perkin-Elmer Applied Biosystems, Foster
City, CA). Each multiplex real-time RT-PCR was carried out
in triplicate in a 30 μl volume [2X ABsolute QPCR ROX
Mix (ABgene, Rochester, NY), 0.1 μg/μl of each primer,
20 μM TaqMan probe, 5 U Reverse-iT Rtase Blend (ABgene),
100 ng total RNA] for 30 min at 48˚C for reverse trans-
cription, 10 min at 95˚C for initial denaturing, followed
by 40 cycles of 95˚C for 15 sec and 60˚C for 1 min in the
ABI PRISM 7700 Sequence Detection System (Perkin-
Elmer Applied Biosystems). Values for Wt1 expression
were subtracted from the same-tube expression of Gapdh
and relative quantitation of the individual reactions were
normalized to GN6TF-11neoCX4 mRNA using the Com-
parative (2ΔΔCt) method described in User Bulletin #2: ABI
Prism 7700 Sequence Detection System. The following
primers and probes were used: rat Gapdh forward, 5'-ATG
GGT GTG AAC CAC GAG AA-3', reverse, 5'-GGC ATG
GAC TGT GGT CAT GA-3', probe, 5'-tet TGC ATC CTG
CAC CAC CAA CTG CTT AG-3' tamra, and rat Wt1
forward, 5'-TCT TCC GAG GCA TTC AGG AT-3', reverse,
5'-TTC AGA TGC TGA CCG GAC AA-3', probe, 5'-fam
CCA CTC CAG ATA CGC GCC GCA-3' tamra. Semi-
quantitative RT-PCR was performed as described previously
(11). RNA (1 μg) was reversed-transcribed with RETRO
script (Ambion, Austin, TX). PCR reactions consisted of
2 μl RT reaction in 50 μl of a buffer consisting of 50 mM
KCl, 20 mM Tris-HCl (pH 8.4), 2 mM MgCl2, 200 μM of
each dNTP (EasyStart PCR Mix-in-a-Tube, Molecular Bio-
Products, San Diego, CA), 0.4 μM of each primer, and 2.5 U
AmpliTaq enzyme (Perkin-Elmer Applied Biosystems).
Amplifications were carried out in a Perkin-Elmer Thermo-
cycler using a step-cycle program consisting of 30 cycles
of 94˚C for denaturing (1 min), 55-65˚C for annealing
(1 min) and 72˚C for extension (2 min). PCR products were
fractionated on 2% agarose gels containing 40 mM Tris-
acetate/1 mM EDTA (pH 8.0) and visualized by ethidium
bromide staining. The following primers were used: hSYT13
forward, 5'-TTA ACA ATG TGG ACA TCT GTT TAGA-3',
reverse, 5'-TTA GTC TAT GAC ATC TGG CTA CATG-3'
(11); PRDM11 forward, 5'-CTT GGG GAT GAC CTC
GTT TA-3', reverse, 5'-AAA GCT TCC AGC AAG TGG
AC-3'; TP53I11 forward, 5'-TGT GGA ACG CTC TCT
ACA CG-3', reverse 5'-TTC GGC CGA CTT GGT AAT
AG-3'; and ß-actin forward, 5'-AGA GAT GGC CAC GGC
TGC TT-3', reverse, 5'-ATT TGC GGT GGA CGA TGG
AG-3' (11). Unless otherwise noted, oligodeoxynucleotide
primers were designed using the Primer3 PCR primer
program (http://frodo.wi.mit.edu/) (20).
Affymetrix microarray analysis. Large-scale gene expression
analysis was performed by Expression Analysis (Durham,
NC) (www.expressionanalysis.com) using the Affymetrix
GeneChip Rat Genome 230 2.0 Array (Affymetrix, Santa
Clara, CA). Target RNA was prepared and hybridized
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Figure 1. Design of SYT13-i and SYT13-s short hairpin RNAs. (a) The SYT13 protein contains an N-terminal transmembrane region (designated TMR)
followed by a cytoplasmic linker region and two tandem C2 domains (designated C2A and C2B). (b) The SYT13 gene is comprised of 6 exons. The
correspondence between the exon structure and the protein structure of SYT13 is indicated. (c) The 21 nucleotide SYT13 target localizes to the coding
sequence of exon 2, which corresponds to the linker region of the protein. The target sequence is indicated in bold/underlined. (d) The sequence and
structure of SYT13-i and SYT13-s shRNAs. The four scrambled nucleotides of SYT13-s are shown in bold/underlined.
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according to the Affymetrix Technical Manual as previously
described (21) and statistical analysis was performed by
Expression Analysis proprietary methods. Expression levels
of select genes (including interferon-associated genes and
potential off-target genes) were mined from the microarray
data.
Western blot analysis. A rabbit polyclonal antibody directed
against hSYT13 was generated by Anaspec (San Jose, CA).
The antibody was raised against a 14 amino acid sequence
(RDQDPDLEKAKPSL) located in the linker region between
the transmembrane and C2A domains of hSYT13
(corresponding to amino acids 41-57). This peptide target
was chosen based on its antigenicity and divergence from the
rSyt13 homolog (57%, 8/14 amino acids). Rabbits (n=2)
were initially immunized with 4 mg KLH-conjugated peptide
in Complete Freund's Adjuvant, and subsequently immunized
at 3, 6 and 10 weeks with the KLH-conjugated peptide in
incomplete Freund's Adjuvant. Serum was collected 7 and
11 weeks after the initial immunization.
Cells intended for Western blot analysis were lysed in
RIPA buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS] and
subjected to Western analysis using standard methods.
Protein concentrations were determined using the BCA
protein assay (Pierce, Rockford, IL). Lysates (50 μg protein)
were fractioned by SDS-PAGE on 10% polyacrylamide
resolving gels and transferred to nitrocellulose membrane
(BA85, 0.45 μm pore size, Schleicher & Schuell, Keene,
NH). The hSYT13 antibody was used at a dilution of 1:1000
in 5% milk/TBST [10 mM Tris-HCl (pH 8.0), 0.15 M NaCl,
0.05% Tween-20]. Bound primary antibody was detected
using a goat anti-rabbit IgG peroxidase conjugate (Sigma
Chemical Company, St. Louis, MO, A-9169; 1:10,000) and
visualized by chemiluminescence using the Amersham
ECL kit (GE Healthcare, Buckinghamshire, UK).
Phenotypic characterization of shRNA-transfected cell lines.
The morphologies of cells in culture were evaluated by
phase contrast microscopy. For determination of saturation
densities in monolayer cultures, cells were plated at a
density of 1.25x105 cells/60-mm dish and maintained in
culture with medium changes every 3 days. At the end of
14 days, cells were harvested and counted using a Model
Z1 particle counter (Beckman Coulter, Fullerton, CA).
Anchorage-independent growth was assayed as described
previously (15). To determine tumorigenicity of the cell
lines, suspensions containing 1x106 cells were injected
into dorsal subcutaneous tissue of 1-day-old Fischer 344
rats (Charles River Laboratories, Inc., Wilmington, MA).
Animals were euthanized when tumors reached an
approximate diameter of 1 cm or after 10 months. Studies
involving the use of animals were carried out in accordance
with federal and institutional guidelines put forth by the
National Institutes of Health and the Institutional Animal
Care and Use Committee of the University of North Carolina
at Chapel Hill.
Statistical analysis. Data in the text, table and figures
represent mean values ± the standard error of the mean.
Statistical analysis of real-time PCR data was accomplished
using one-way ANOVA (KaleidaGraph, Reading, PA). The
statistical significance of linear correlation coefficients was
calculated using VasserStats Significance of Correlation
Coefficient Calculator (http://faculty.vasser.edu/lowry/
rsig.html). The statistical significance of data from saturation
density and anchorage-independent growth assays was
assessed using the Student's t-test for unpaired data with
unequal variance (KaleidaGraph). Statistical significance
associated with Kaplan-Meier survival analysis was
determined using the log-rank test (GraphPad Prism, San
Diego, CA).
Results
SYT13 expression in SYT13-i and SYT13-s cell lines.
Introduction of human chromosome 11 into the tumorigenic
GN6TF cell line resulted in suppressed microcell hybrid
cell lines, including GN6TF-11neoCX4 (8). Selected GN6TF-
11neoCX4-derived transfected cell lines that carry the psiRNA
vectors for SYT13-targeting (designated SYT13-i3, SYT13-i5,
SYT13-i6 and SYT13-i12) or scrambled-control (designated
SYT13-s1 and SYT13-s8) were expanded and SYT13 knock-
down was assessed by Western blot. The SYT13 protein is
approximately 66 kDa in size (22,23), but synaptotagmin
protein family members are known to form SDS-resistant
dimers (24). Both monomeric and dimeric forms of immuno-
reactive hSYT13 protein were detected in GN6TF-11neoCX4
SYT13-i and SYT13-s cell lines using anti-SYT13 antibodies
(Fig. 2a). The anti-SYT13 antibody was designed for human
SYT13 specificity, but recognizes the rat Syt13 protein in
GN6TF cells (Fig. 2a). GN6TF cells express significantly
reduced levels of rSyt13 protein compared to GN6TF-
11neoCX4 cells, and there is a complete absence of the dimeric
form of the protein. The amount of SYT13 detected in
GN6TF-11neoCX4 cells reflects the contribution of the human
allele in the microcell hybrid cell line. All SYT13-i cell lines
examined (SYT13-i3, SYT13-i5, SYT13-i6 and SYT13-i12)
express less SYT13 protein than the GN6TF-11neoCX4 cells
(Fig. 2a). The diminished SYT13 protein level among these
cell lines was most pronounced when the dimeric form of the
protein is considered (Fig. 2a). In contrast, the SYT13-s cell
lines examined (SYT13-s1 and SYT13-s8) express levels of
SYT13 protein that are similar or indistinguishable from
that observed in GN6TF-11neoCX4 cells (Fig. 2a).
Short hairpin RNA-mediated interferon response and
potential off-target effects. Transfection of cells with
shRNA can result in an interferon response (25-27) or off-
target effects (28). In studies that have shown an interferon
response to shRNA transfection, numerous interferon-
associated genes were found to be induced 2- to 5-fold
(27). The gene expression profile of both SYT13-i and
SYT13-s cell lines (including SYT13-i3, SYT13-i5, SYT13-i12
and SYT13-s1) were evaluated by microarray analysis to
determine the levels of expression of 35 interferon-associated
genes. There was minimal change in gene expression for
these genes among SYT13-i and SYT13-s cells when compared
to GN6TF-11neoCX4 cells; 34/35 (97%) interferon-associated
genes were expressed at levels equal to or less than that
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observed in GN6TF-11neoCX4 cells (data not shown), and
the other (Isg20, interferon stimulated exonuclease 20) was
modestly induced (2-fold). These results suggest that minimal
interferon-associated gene expression changes accompany
the transfection of SYT13-i or SYT13-s shRNA expression
vectors in GN6TF-11neoCX4 cells.
siRNAs have been reported to affect translation of
unintended transcripts containing partial complementarity
to targets (29,30). A BLAST search (http://www.ncbi.nlm.
nih.gov/blast/) of the 21 nucleotide sequences corresponding
to the SYT13-i target and SYT13-s scrambled control
identified several potential off-target genes in the rat genome.
The SYT13-i target matched 31 potential off-target genes
with 14/21 (67%) to 18/21 (86%) sequence identity (67%,
n=14; 71%, n=8; 76%, n=5; 81%, n=1; 86%, n=3). Likewise,
the SYT13-s control matched 25 potential off-target genes
with 67-86% sequence identity (67%, n=9; 71%, n=5; 76%,
n=4; 81%, n=6; 86%, n=1). Overall, the SYT13-i and SYT13-s
shRNAs match 33 off-target genes with >15/21 (71%)
sequence identity. However, microarray analysis failed to
show significant alterations in mRNA levels of these potential
off-target genes, suggesting minimal off-target effects from
these shRNAs.
Molecular analysis of SYT13-i and SYT13-s cell lines. RNA
samples corresponding to Zeocin-resistant SYT13-i and
SYT13-s clones were analyzed by semi-quantitative and
real-time RT-PCR to determine RNAi-mediated alterations
in the expression of several genes, including human genes
(PRDM11 and TP53I11) carried on human 11p11.2
(proximal to SYT13) and rat Wt1, which has been implicated
in 11p11.2-mediated tumor suppression in our model system
(14). SYT13, PRDM11 and TP53I11 are located within a
~350 kbp region of human 11p11.2. Semi-quantitative RT-
PCR analysis of PRDM11 and TP53I11 failed to detect any
change in expression of these genes between GN6TF-
11neoCX4 cells and the SYT13-i and SYT13-s cell lines
analyzed (including SYT13-i3, SYT13-i5, SYT13-i6, SYT13-
i12, SYT13-s1 and SYT13-s8), suggesting that knockdown of
SYT13 does not result in secondary alterations in the
mRNA expression of these genes (data not shown).
Our previous studies identified a correlation between
human 11p11.2-mediated rat liver tumor suppression and
induction of rat Wt1 (14). Based on this observation we
hypothesized that the molecular mechanism governing rat
liver tumor suppression by human 11p11.2 may directly or
indirectly involve this previously identified tumor suppressor
gene (14). Thus, if the microcell-mediated introduction of
SYT13 into the cells is responsible for the induction of Wt1,
we expect the expression of Wt1 to be diminished in SYT13-
attenuated cell lines. The parental GN6TF tumor cells
express Wt1 at a significantly lower level than the suppressed
GN6TF-11neoCX4 cells (Fig. 2b). Likewise, the level of Wt1
mRNA was significantly decreased in cell lines transfected
with SYT13-i constructs, but was unchanged (or higher) in
SYT13-s cell lines (Fig. 2b). The loss of Wt1 expression
concurrent with attenuation of SYT13 was most pronounced
in SYT13-i6 and SYT13-i12 (Fig. 2b). Furthermore, the
expression of Wt1 significantly correlates with the level
of SYT13 protein found in the SYT13-i and SYT13-s cell
lines evaluated (R=0.79, p=0.035). These data: i) support
our previous hypothesis that expression of Wt1 is directly
or indirectly regulated in response to hSYT13 in this model
system; and ii) suggest strongly that Wt1 is an important
down-stream effector of SYT13-mediated tumor suppression.
Phenotypic and growth characteristic analyses of SYT13-i
and SYT13-s cell lines in vitro. Analysis of morphology,
contact inhibition, and anchorage-dependent growth in
GN6TF-11neoCX4 cells revealed that human 11p11.2
normalizes the aggressive phenotype of the GN6TF cells
in vitro (13,14). After targeting human SYT13 in GN6TF-
11neoCX4 cells with shRNAs, we re-examined these
characteristics to assess the contribution of SYT13 to the
suppression of the neoplastic cell phenotype of GN6TF
cells in vitro. GN6TF cells are spindle-shaped and grow in
multiple layers, whereas GN6TF-11neoCX4 cells exhibit a
flattened and polygonal cell morphology and produce a
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Figure 2. Molecular characterization of SYT13-i and SYT13-s cell lines.
(a) Western analysis of SYT13 protein expression in GN6TF, GN6TF-
11neoCX4 microcell hybrid cells, SYT13-i and SYT13-s cell lines. The
migration of the monomeric (66 kDa) and dimeric (130 kDa) forms of
SYT13 are indicated. (b) Quantitative real-time RT-PCR analysis of Wt1
expression in SYT13-i and SYT13-s cell lines expressed relative to GN6TF-
11neoCX4 cells. *p<0.05 compared to GN6TF-11neoCX4 cells using the one-
way ANOVA.
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contact-inhibited growth pattern (Fig. 3a). SYT13-i cell lines
retain some polygonal features similar to GN6TF-11neoCX4
cells, but exhibit a multilayer growth pattern after reaching
confluence in culture (Fig. 3a). The morphologies of control-
transfected cell lines (SYT13-s1 and SYT13-s8) were similar
to that of the parental suppressed cell line GN6TF-11neoCX4
(Fig. 3a). Fig. 3b shows the saturation densities of the SYT13-i
and SYT13-s cell lines analyzed. SYT13-i5 and SYT13-i12
grow to an elevated saturation density that is indistin-
guishable from GN6TF, reflecting multilayer growth. In
contrast, the saturation densities of SYT13-s1 and SYT13-s8
were indistinguishable from that of the GN6TF-11neoCX4
cells. Fig. 3c shows the anchorage-independent growth
potential of the SYT13-i and SYT13-s cell lines analyzed.
All of the SYT13-i cell lines efficiently produced colonies in
soft agarose, indicative of the restoration of anchorage-
JAHN  and COLEMAN:  SYT13 ATTENUATION PROMOTES LIVER TUMORIGENESIS446
Figure 3. Phenotypic characterization of SYT13-i and SYT13-s cell lines. (a) Phase contrast microscopy of GN6TF tumor cells, GN6TF-11neoCX4 microcell
hybrid cells, and representative derived SYT13-i and SYT13-s transfected cell lines. (b) Saturation densities of GN6TF tumor cells, GN6TF-11neoCX4
microcell hybrid cells, and representative derived SYT13-i and SYT13-s transfected cell lines (expressed relative to GN6TF-11neoCX4 cells). (c) Anchorage-
independent growth of GN6TF cells, GN6TF-11neoCX4 microcell hybrid cells, and representative SYT13-i and SYT13-s transfected cell lines (expressed
relative to CX4 cells). (d) Kaplan-Meier analysis of survival for animals transplanted with GN6TF-11neoCX4 cells, SYT13-i12 and SYT13-i5 cell lines.
*p<0.05 and **p<0.001 compared to GN6TF-11neoCX4 cells using Student's t-test (unpaired data with unequal variance); p-values for (d) are compared to
GN6TF-11neoCX4 cells using the log-rank test.
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independent growth potential (Fig. 3c). SYT13-i12 formed
the most soft agarose colonies, comparable to the number
observed with GN6TF cells. In contrast, SYT13-s1 and
SYT13-s8 cells formed few colonies in soft agarose, similar
to GN6TF-11neoCX4 cells (Fig. 3c). These results combine to
suggest that several cellular features of suppressed GN6TF-
11neoCX4 microcell hybrid cells (including growth pattern,
contact inhibition and anchorage-dependent growth) correlate
with expression of SYT13, and may be directly or indirectly
regulated by SYT13.
Tumorigenic potential of SYT13-i and SYT13-s cell lines
in vivo. Several SYT13-i and SYT13-s cell lines were selected
for analysis of tumorigenicity in vivo. SYT13-i5 and SYT13-i12
cells displayed the greatest tumorigenic potential with 86
and 80% of syngeneic animals (respectively) developing
tumors with short latency (Table I). In contrast, the suppressed
parental GN6TF-11neoCX4 cells developed fewer tumors
with a much longer average latency, consistent with previous
studies (8). The average latency for tumor formation by
SYT13-s1 and SYT13-s8 cells in the 50% (4/8) of animals
which developed tumors was 226±31 days, similar to the
GN6TF-11neoCX4 cells (Table I). The increased aggres-
siveness of SYT13-i cell lines was evident from a Kaplan-
Meier analysis of survival after transplantation of SYT13-i
cell lines (Fig. 3d). This analysis revealed a statistically
significant survival disadvantage for animals transplanted
with SYT13-i5 cells (p=0.04) compared to GN6TF-11neoCX4
cells (Fig. 3d). Likewise, a trend suggestive of survival
disadvantage was observed among animals transplanted
with SYT13-i12 cells (compared to GN6TF-11neoCX4 cells),
but the trend did not reach significance (p=0.15).
Discussion
Synaptotagmin XIII is an atypical member of the
synaptotagmin family of membrane-associated synaptic
vesicle transport proteins which largely serve as Ca2+ sensors
in vesicular trafficking and exocytosis (22,31). The function
of SYT13 is unknown, but appears to lack some conserved
functions of other family members (22,23), including calcium-
dependent phospholipid binding in vesicle transport and
calcium-independent binding to target SNARE heterodimers
during calcium-triggered membrane fusion (32). We have
identified a potential role for SYT13 in liver tumor sup-
pression. The human chromosome 11 liver tumor suppressor
locus was identified through deletion mapping of microcell
hybrid cell lines derived from GN6TF rat liver tumor cells
(9). The minimal liver tumor suppressor region of human
11p11.2 contains a number of potential candidate tumor
suppressor genes (10-12). However, transcription mapping
of suppressed and non-suppressed microcell hybrid cell
lines reduced the number of viable candidate genes and
produced evidence suggesting that SYT13 is the best
candidate for the human 11p11.2 liver tumor suppressor
(11). hSYT13 is expressed in suppressed microcell hybrid
cell lines, but not in non-suppressed microcell hybrid cell
lines (11). Additionally, hSYT13 was not expressed in one
microcell hybrid cell line that was determined to have an
interstitial deletion in the human 11p11.2 liver tumor
suppressor region (11,13). Thus, our studies indicate that
expression of hSYT13 accompanies 11p11.2-mediated liver
tumor suppression, strongly suggesting that SYT13
contributes directly or indirectly to tumor suppression in this
model system. GN6TF cells are highly tumorigenic in vivo
(100% of host animals develop tumors with short latency)
and exhibit aggressive phenotypic characteristics in vitro,
including loss of contact inhibition, growth to elevated
saturation density and anchorage-independent growth
(15,33). Suppression of the neoplastic phenotype of GN6TF
cells by introduction of human chromosome 11 results in
reduced tumorigenic potential (fewer tumors formed with
longer latency), and normalization of the cell phenotype
in vitro (restoration of contact inhibition, reduction of
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Table I. Tumorigenic potential of GN6TF-11neoCX4 and derived SYT13-i and SYT13-s cell lines following transplantation into
neonatal Fischer 344 rats.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Cell Line Tumorigenicitya Average latency Latency range Latency significance Survival significance
(%) (days) (days) (P)b (P)c
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
GN6TF-11neoCX4 4/6 (67) 274±11 256-293 - -
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
SYT13-i3 1/5 (20) 201 NAd NA 0.10 (NS)e
SYT13-i5 6/7 (86) 144±14 110-201 <0.0001 0.04
SYT13-i6 1/8 (12) 201 NA NA 0.07 (NS)
SYT13-i12 8/10 (80) 164±25 87-293 0.002 0.15 (NS)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
SYT13-s1 1/4 (25) 256 NA NA 0.28 (NS)
SYT13-s8 3/4 (75) 216±41 153-293 0.28 (NS) 0.48 (NS)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aTumorigenic potential is expressed as the percentage of animals forming tumors per total animals receiving cell transplants. bCompared
to GN6TF-11neoCX4 cells using the Student's t-test. cCompared to GN6TF-11neoCX4 cells using the log-rank test. dNot applicable; enot
significant.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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saturation density, and loss of anchorage-independent
growth potential) (8). As summarized in Fig. 4, when
human 11p11.2 is introduced into GN6TF cells (resulting in
suppressed microcell hybrid cell lines), hSYT13 is expressed
coordinate with suppression of tumorigenicity and
normalization of the cellular phenotype. In previous studies,
re-expression of tumorigenicity in suppressed microcell
hybrid cell lines followed loss of the suppressive human
11p11.2 chromosome (8), and the related loss of hSYT13
expression (11). In the current study, we show that RNAi-
mediated silencing of SYT13 results in re-expression of the
neoplastic phenotype of GN6TF tumor cells (Fig. 4). This
result suggests strongly that SYT13 directly or indirectly
regulates the growth properties of these cells in vitro and
that loss of SYT13 significantly contributes to tumorigenic
potential in vivo. GN6TF tumor cells express the monomeric
species of rSyt13 at easily detectable levels (Fig. 2a), but
this protein fails to form dimers. Expression of exogenous
hSYT13 (from human 11p11.2) results in the production of
both monomeric protein and dimeric complexes (Fig. 2a).
In the presence of a dimeric form of SYT13, a molecular
defect in GN6TF tumor cells is complemented (and corrected)
by a gene from human 11p11.2, resulting in suppression
of tumorigenicity. These observations suggest that: i) the
endogenous rSyt13 may be defective or non-functional,
possibly as a consequence of a missense mutation in the
rSyt13 gene; ii) the dimeric form of the rSyt13 protein is
required for expression of its tumor suppressive functions;
and iii) the endogenous rSyt13 in GN6TF cells is unable to
dimerize, resulting in loss of tumor suppressor function.
The molecular mechanism for human 11p11.2-mediated
liver tumor suppression has not yet been fully elucidated.
However, our previous studies identified a precise correlation
between Wt1 expression and suppression of tumorigenicity
among microcell hybrid cell lines, suggesting that the
molecular mechanism governing human 11p11.2-mediated
liver tumor suppression may directly or indirectly involve the
induction of rat Wt1 (14). The current study supports this
hypothesis. In response to RNAi-mediated attenuation of
SYT13, Wt1 expression levels decline coordinate with re-
expression of the neoplastic phenotype. This observation
suggests a mechanistic linkage between SYT13 and Wt1.
The function of SYT13 is unknown. However, Fukuda and
Mikoshiba have suggested that this membrane-associated
protein is involved in a constitutive pathway that docks
transport vesicles to plasma membranes (22). Thus, SYT13
may function in cellular signaling, relaying extracellular
signals to the nucleus and eventually contributing to the
regulation of transcription. The current study suggests that
the rSyt13 expressed in GN6TF cells may be defective (non-
functional) as a consequence of some as yet unidentified
mutation that results in a failure (or inability) of the protein
to dimerize. It is intriguing to speculate that the loss of
rSyt13 function interrupts normal cell signaling, resulting
in loss of expression of other genes, such as Wt1. It follows
that expression of a functional hSYT13 in these cells would
restore normal signaling, resulting in re-expression of Wt1.
However, additional studies will be required to establish a
direct linkage between SYT13 (either the monomeric or
dimeric form) and regulation of Wt1 transcription.
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